Medipost said Monday that its consolidated revenue for the third quarter of this year reached 19.2 billion won, a 2.8% increase from the same period last year. The operating loss for the third quarter was 19.8 billion won, and the net loss was 36.3 billion won.
Medipost's cumulative revenue for the first three quarters of this year was 57.5 billion won, with a cumulative operating loss of 61 billion won.
Based on cumulative revenue for the first three quarters of this year, the product mix is as follows: cord blood banking accounts for 52.5% (30.1 billion won), stem cell therapies account for 22.8% (13.1 billion won), and health functional foods account for 14.1% (8.1 billion won).
Regarding its performance this year, Medipost explained that the results reflect research and development (R&D) and clinical trial costs incurred to enter the U.S. and Japanese markets.
In fact, Medipost's R&D expenses increased from 56.8 billion won in 2024 to 72.5 billion won last year, reaching a cumulative 64.5 billion won for the first three quarters of this year.
The ratio of R&D expenses to revenue rose from 80.4% in 2024 to 98.4% last year, and reached 112.3% cumulatively for the first three quarters of this year.
Medipost particularly emphasized that it has begun intensifying key investments for the global commercialization of "Cartistem," its stem cell therapy for knee osteoarthritis, in the third quarter of this year.
The company stated that it is currently conducting final data organization work for a marketing authorization application based on the results of Phase 3 clinical trials successfully completed in Japan.
Additionally, it has been executing routine R&D expenses related to patient treatment and dosing procedures for Phase 3 clinical trials in the United States.
A Medipost official said, "The increase in R&D costs is not a simple one-time expense, but part of a strategic preemptive investment to secure leadership in the global biopharmaceutical market and prove unique technological value."
The official added, "In the third quarter, significant core clinical and regulatory preparation costs were reflected to complete the commercialization of Cartistem in the U.S. and Japan."
The official further stated, "We will flawlessly complete the ongoing Phase 3 clinical dosing in the U.S. and the preparation for the marketing authorization application in Japan, thereby significantly enhancing corporate and shareholder value."